$VRTX T1D progressing nicely, ways off from it impacting top/bottom line but potential blockbuster, likely larger than CF. Let’s see what the pain trials have in store.
@crisprtalk I tend to be pretty conversative with my price targets. I'd been my clear skies target around 420 w/ strong uptake in sickle cell in Europe and than US in back half of the year. 350 is based on guidance, though I expect 2x beat and raises just like previous years, not included pt
@crs1 the rest of the market has shrinking market cap, this has the same market cap yet for cut by 75% in share price value. Understand the difference between share price and market cap